Pharmacokinetics, Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 2 Years of Age
Public ClinicalTrials.gov record NCT01773174. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Single Dose Open-label PK/PD, Safety and Tolerability Study of Dabigatran Etexilate Mesilate Given at the End of Standard Anticoagulant Therapy in Children Aged 1 Year to Less Than 2 Years in Conjunction With Study 1160.89
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Study will assess PK/PD parameters and safety and tolerability of the study medication in this age group
Study identification
- NCT ID
- NCT01773174
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 1 Year to 2 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2013 (Type not available)
- Primary completion
- Dec 2015 (Estimated)
- Completion
- Dec 2015 (Estimated)
- Last update posted
- Oct 26, 2015
2013 – 2015
United States locations
- U.S. sites
- 8
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1160.145.00010 Boehringer Ingelheim Investigational Site | Sacramento | California | — | — |
| 1160.145.00009 Boehringer Ingelheim Investigational Site | Louisville | Kentucky | — | — |
| 1160.145.00008 Boehringer Ingelheim Investigational Site | Boston | Massachusetts | — | — |
| 1160.145.00012 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 1160.145.00007 Boehringer Ingelheim Investigational Site | Newark | New Jersey | — | — |
| 1160.145.0006 Boehringer Ingelheim Investigational Site | Pittsburgh | Pennsylvania | — | — |
| 1160.145.00001 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 1160.145.00011 Boehringer Ingelheim Investigational Site | Spokane | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01773174, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 26, 2015 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01773174 live on ClinicalTrials.gov.